Figueroa et al., medRxiv,
doi:10.1101/2021.04.13.21255409 (Preprint)
Efficacy of a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease A pragmatic multicenter, randomized, double-blind, placebo-controlled trial (CARR-COV-02)
Prophylaxis RCT with 394 healthcare workers, 196 treated with iota-carrageenan, showing significantly lower symptomatic cases with treatment. There were no deaths or hospitalizations. There was a significant number of PCR- symptomatic cases (7.6% treatment and 8.6% control). The two treatment cases occurred shortly after randomization - infection may have occurred before the start of treatment. CARR-COV-02.
NCT04521322.
Figueroa et al., 4/15/2021, Double Blind Randomized Controlled Trial, Argentina, South America, preprint, 18 authors.
risk of symptomatic case, 79.8% lower, RR 0.20, p = 0.04, treatment 2 of 196 (1.0%), control 10 of 198 (5.1%).
Effect extraction follows
pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.